Ontario Patients – Please join us for our very first Patient Empowerment Pilot Project Workshop.
The Phase I Gene Therapy Study for Fabry Disease is looking to recruit interested patients. This is a first-in-human study for the treatment of Fabry disease.
Exciting news for the CFA Community – Replagal has been approved by Health Canada as of February 2017 and all patients have been transitioned from the REP-081 study at this point. Replagal is a long-term Enzyme Replacement Therapy (ERT), the infusion will be given every 2 weeks, treatment time being approximately 4o minutes. It is […]
We are committed to improving the lives of those who live with and are affected by Fabry disease in Canada.
Subscribe error, please review your email address.Close
You're now subscribed, thank you!Close
There was a problem with your submission. Please check the field(s) with red label below.Close
Your message has been sent. We'll get back to you soon!Close